GEN Exclusives

More »

GEN News Highlights

More »
Apr 11, 2007

Novosom to Option CD40-Targeted Antisense Inhibitors from Isis

  • Novosom purchased an exclusive option from Isis Pharmaceuticals related to antisense inhibitors targeting the CD40 membrane protein for all indications. If exercised within six months, Novosom will acquire an exclusive, worldwide license.

    CD40 is a validated target for both inflammatory diseases and B-cell cancers. Novosom plans to target CD40 for indications such as Crohn's disease, transplant, rheumatoid arthritis, cancer, and multiple sclerosis. If acquired, the license from Isis would include rights to the target and to oligonucleotides targeting CD40 and incorporating Isis' second-generation antisense chemistry, 2' MOE oligonucleotides. 

    Novosom is using its Smarticles® technology to enable systemic delivery of antisense targeting CD40. This encapsulated antisense approach has demonstrated targeted delivery to specific cell types with a rapid onset of action, according to the company.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?